Regarding the interactions that were decreased in MS patients compared to controls, PBMCs from patients with MS showed lowered inhibition of STAT5 by LCK suggesting impairment of the regulation of T/B cell signaling and IL-2 trophic effects [52] or cytotoxicity [53], as well as the regulation of the ubiquitination system modulated by CBL-B [54]. The gene discussed is CBLB; the disease is myeloid sarcoma.